About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Advertisement

Medindia » Health Press Releases A-Z

Global Therapeutic Drug Monitoring Report 2017-2026: Unmet Needs and Strategies for Development of Markets for TDM

Advertisement

Advertisement

Advertisement

Sponsored Post and Backlink Submission

Latest Press Release on Drug News

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

BE HEARD I and BE HEARD II are the first Phase 3 trials to evaluate the efficacy and safety of an IL-17A and IL–17F inhibitor, BIMZELX ® (bimekizumab-bkzx), in the treatment of adult ...

New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance

AMSTERDAM , May 23, 2024 /PRNewswire/ -- The race to create replacement antibiotics and antifungals to combat superbugs is falling dangerously short, putting people across the world a...

Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy

SUZHOU, China , May 21, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship progra...

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

SAN FRANCISCO and SUZHOU, China , May 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufa...

Rila Therapeutics Announces Dosing of First Cohort in Phase 1 Clinical Trial of RLA-23174, a First-In-Class HIPK2 Allosteric Inhibitor, For Treatment of Chronic Kidney Disease and Fibrosis

SOUTH SAN FRANCISCO, Calif. , May 20, 2024 /PRNewswire/ -- Rila Therapeutics, Inc., A biotechnology company focused on addressing the burden of chronic fibrotic diseases, today an...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close